Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Prasugrel and ticagrelor, new P2Y12-ADP receptor antagonists, are associated with greater
pharmacodynamic inhibition and reduction of cardiovascular events in patients with an acute
coronary syndrome. However, evidence is lacked about the effects of achieving faster and
stronger cyclooxygenase inhibition with intravenous lysine acetylsalicylate (LA) compared to
oral aspirin on prasugrel inhibited platelets. Recently, we demonstrated in healthy
volunteers that the administration of intravenous LA resulted in a significantly reduction of
platelet reactivity compared to oral aspirin on prasugrel inhibited platelets. Loading dose
of LA achieves platelet inhibition faster, greater and with less variability than aspirin.
However, there are no data of this issue in patients with an ST-segment elevation myocardial
infarction (STEMI). The ECCLIPSE-STEMI trial will study the effect of LA versus aspirin in
platelet reactivity in patients with STEMI